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1. Introduction 
This chapter concerns influences of inhibitors and activators on carbonic anhydrase 
isoenzymes of various living systems. Carbonic anhydrase (EC 4.2.1.1., CA) is a pH 
regulatory/metabolic enzyme in all life kingdoms, found in organisms all over the 
phylogenetic tree (Supuran, 2008a,b,c) catalyzing the hydration of carbon dioxide to 
bicarbonate and the corresponding dehydration of bicarbonate in acidic medium with 
regeneration of CO2 (Sly and Hu, 1995). 16 isozymes have been described up to now in 
mammals, the most active ones as catalysts for carbon dioxide hydration being CA II and 
CA IX (Sly and Hu, 1995; Ozensoy et al., 2004; Bayram et al., 2008; Senturk et al., 2009; 
Hilvo et al, 2008). The sixteen isozymes differ in their subcellular localization, catalytic 
activity and susceptibility to different classes of inhibitors. Some of them are cytosolic (CA 
I, CA II, CA III, CA VII and CA XIII), others are membrane bound (CA IV, CA IX, CA XII 
and CA XIV), two are mitochondrial (CA VA and CA VB), and one is secreted in saliva 
(CA VI). It has been reported that CA XV isoform is not expressed in humans or in other 
primates, but it is abundant in rodents and other vertebrates (Table 1.) (Nair et al., 1994; 
Parkkila et al., 1996; Pastorekava et al., 2004; Bayram et al., 2008; Innocenti et al., 2008a,b; 
Senturk et al., 2009; Ekinci et al., 2011). CAs are produced in a variety of tissues where 
they participate in several important biological processes such as acid-base balance, 
respiration, carbon dioxide and ion transport, bone resorption, ureagenesis, 
gluconeogenesis, lipogenesis and body fluid generation (Supuran, 2008a,b,c). CA 
isozymes involved in these processes are important therapeutic targets with the potential 
to be inhibited / activated for the treatment of a range of disorders such as edema, 
glaucoma, obesity, cancer, epilepsy and osteoporosis (Innocenti et al., 2008b; Ekinci et al., 
2007; Ekinci et al., 2011). 
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Isozyme 
Catalytic activity 
(CO2 hydration) 
Affinity for 
sulfonamides 
Sub-cellular localization 
CA I Low (10%of thatof CAII) Medium Cytosol 
CA II High Very high Cytosol 
CA III Very low (0.3%of thatof CAII) Very low Cytosol 
CA IV High High Membrane-bound 
CA VA Moderate-higha High Mitochondria 
CA VB Moderate High Mitochondria 
CA VI Moderate Medium-High Secreted into saliva/milk 
CA VII High Very high Cytosol 
CARP VIII Acatalytic * Cytosol 
CA IX High High Membrane-bound 
CARP X Acatalytic * Cytosol 
CARP XI Acatalytic * Cytosol 
CA XII Medium-Low  Very high Membrane-bound 
CA XIII LOW High Unknown 
CA XIV Moderate High Membrane-bound 
aModerate at pH 7.4, high at pH 8.2 or higher. 
bCA XIII has not been isolated as a protein but has been identified from an expressed sequence tag (EST) 
derived from a mouse mammary gland cDNA library. 
*The native CARP isozymes do not contain Zn (II), so that their affinity for the sulfonamide inhibitors 
has not been measured. By site-directed mutagenesis it is possible to modify these proteins and 
transform them in enzymes with CA-like activity which probably are inhibited by sulfonamides, but no 
studies on this subject are available presently. 
Table 1. Higher vertebrate ǂ-CA isozymes, their Relative CO2 hydrase activity, affinity for 
sulfonamide inhibitors, and sub-cellular localization 
In addition to the physiological reaction, the reversible hydration of CO2 to bicarbonate 
(reaction 1, Scheme 1), CAs catalyze a variety of other reactions, such as: the hydration of 
cyanate to carbamic acid, or of cyanamide to urea (reactions 2 and 3); the aldehyde 
hydration to gem-diols (reaction 4); the hydrolysis of carboxylic, or sulfonic (reactions 5, 6), 
as well as other less investigated hydrolytic processes, such as those described by equations 
7-10 in Scheme 1 (Supuran et al., 1997; Supuran and Scozzafava, 2000b; Guerri et al., 2000). It 
should be mentioned that the previously reported phosphatase activity of CA III was 
recently proved to be an artefact (Kim et al., 2000). It is unclear at this moment whether CA 
catalyzed reactions other than the CO2 hydration has physiological significance. 
2. Carbonic anhydrase inhibitors 
As will be discussed shortly, many of these isozymes are important targets for the design of 
inhibitors with clinical applications. CA inhibition with sulfanilamide (1) discovered by 
Mann and Keilin (Krebs, 1948) was the beginning of a great scientific adventure that led to 
important drugs, such as the antihypertensives of benzothiadiazine and high-ceiling 
diuretics type (Supuran 1994), the sulfonamides with CA inhibitory properties mainly used 
as antiglaucoma agents (Krebs, 1948; Supuran, 1994; Mansoor et al., 2000), some antithyroid 
drugs (Krebs, 1948), the hypoglycemic sulphonamides (Maren et al., 1983) and, ultimately, 
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C OO + H2O HCO3- + H+
C NHO + H2O NH2COOH
(1)
(2)
C NHHN + H2O NH2CONH2 (3)
RCHO + H2O RCH(OH)2 (4)
RCOOAr + H2O RCOOH + ArOH (5)
RSO3Ar + H2O RSO3H + ArOH (6)
ArF + H2O HF + ArOH (7)
(Ar = 2,4-dinitrophenyl)
PhCH2OCOCl + H2O PhCH2OH + CO2 + HCl (8)
RSO2Cl + H2O RSO3H + HCl (9)
(R = Me;Ph)
ArOPO3H2 + H2O ArOH + H3PO4 (10)  
 
 
 
 
 
 
Scheme 1. Reactions (1-10) catalyzed by ǂ-CAs. 
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some novel types of anticancer agents (Supuran and Scozzafava, 2000). The report of Krebs 
(1948) that mainly the unsubstituted aromatic sulfonamides of type ArSO2NH2 act as strong 
CAIs, and that the potency of such compounds is drastically reduced by N-substitution of 
the sulfonamide moiety, constituted the beginning of extensive structure-activity 
correlations, which led to some valuable drugs during a short period of time. Among the 
active structures found by Krebs were also the azodyes 2 (prontosil red) and 3, derived from 
sulfanilamide (Maren, 1976; Krebs, 1948; Supuran et al., 2003). The early stages of CAIs 
development have thouroughly been reviewed by Maren (Maren, 1976; Maren, 1967) 
whereas literature till 1993 was reviewed by Supuran (Supuran and Scozzafava, 2000; 
Supuran et al., 2003) and more incompletely (up to 1996) by Mansoor et al. (2000). Thus, in 
this review we will concentrate on the recent developments in this field that led to 
important advances in the design of topically acting antiglaucoma sulfonamides, isozyme-
specific inhibitors, inhibitors with modified sulfonamide moieties, antitumor sulfonamides, 
as well as diagnostic tools and biosensors based on this class of pharmacological agents 
(Supuran et al., 2003). 
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CAs are inhibited by four main mechanisms: (i) coordination of the inhibitor to the Zn(II) 
ion by replacing the zinc-bound water/hydroxide ion and leading to a tetrahedral geometry 
of Zn(II) (e.g., the sulfonamides, Fig. 1A) (Supuran 2008a; Alterio et al., 2009). (ii) Addition 
of the inhibitor to the metal coordination sphere, when the Zn(II) ion is in a trigonal 
bipyramidal geometry (e.g., the thiocyanate adduct, Fig. 1B) (Supuran 2008a; Alterio et al., 
2009). (iii) Anchoring of the inhibitor to the Zn(II)-bound solvent molecule, i.e., a water or 
hydroxide ion (e.g. phenol, Fig. 1C) (Nair et al., 1994) (iv) Occlusion of the CA active site 
entrance, with coumarins (Maresca et al., 2009; Maresca et al., 2010) lacosamide (Temperini 
et al., 2010) and fullerenes (Innocenti et al., 2010) binding in this way, as shown 
schematically in Fig. 1D for a hydrolyzed coumarin derivative (Maresca et al., 2009). All 
these binding modes have been demonstrated by means of X-ray crystallography of 
enzyme-inhibitor adducts (Nair et al., 1994; Supuran, 2008a; Maresca et al., 2009; Durdagi et 
al., 2011). It should be noted that passing from sulfonamides and their bioisosteres 
(sulfamates, sulfamides, etc.) to inhibitors occluding the entrance of the active site, the role 
of the Zn(II) ion is constantly diminishing in its interaction with the inhibitor molecule (Nair 
et al., 1994; Supuran, 2008a; Maresca et al., 2009; Durdagi et al., 2011). This phenomenon has 
important consequences for the drug design of CA inhibitors (CAIs), because the bottom of 
the active site cavity is very much conserved in the 16 CA isozymes described so far in 
mammals, whereas the regions with the highest variation in amino acid sequence, therefore 
the highest degree of structural diversity, are just those at the entrance of the active site 
(Supuran and Scozzafava, 2007b; Supuran, 2008a; Alterio et al., 2009). Indeed, phenols, 
(Ekinci et al., 2010; Durdagi et al., 2011) but also coumarins (Maresca et al., 2009; Maresca et 
al., 2010) and other types of non-zinc binder inhibitors (Alterio et al., 2009; Ekinci et al., 
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2011) were recently shown to lead to isozyme-selective CAIs, a goal difficult to achieve with 
the classical sulfonamide/sulfamate inhibitors (Supuran, 2008a; Zu and Sly, 1990). 
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Fig. 1. Schematic representation for the three main CA inhibition mechanisms: (A) 
Sulfonamides (and their isosteres, sulfamate, and sulfamide) substitute the fourth zinc 
ligand and bind in tetrahedral geometry of the metal ion (Alterio et al., 2009); (B) Inorganic 
anion inhibitors (thiocyanate as an example) add to the metal ion coordination sphere 
leading to trigonal bipyramidal adducts (Alterio et al., 2009); (C) Phenols anchor to the 
Zn(II) coordinated water molecule/hydroxide ion (Nair et al., 1994); (D) Coumarins 
(hydrolyzed in situ to 2-hydroxycinnamic acids) occlude the entrance of the active site 
cavity, interacting both with hydrophilic and hydrophobic amino acid residues. The 
inhibitor does not interact at all with the catalytically crucial Zn(II) ion which is coordinated 
by three His residues and a water molecule (Maresca et al., 2009; Maresca et al., 2010). 
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Fig. 2. CAIs include the classical inhibitors acetazolamide (4), methazolamide,  
(5) ethoxzolamide (6), sulthiame (7) and dichlorophenamide (8). CAIs also include more recent 
drugs/investigational agents such as dorzolamide (9), indisulam (10), topiramate (11), 
zonisamide (12), sulpiride (13), COUMATE (15), saccharin (16). Many of these compounds 
were initially developed years ago during the search for diuretics, among which the thiazides, 
compounds, as well as derivative 14 are stil widely clinically used (Supuran, 2008a). However, 
some of these enzyme inhibitors could also be used for the systemic treatment of glaucoma 
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(see below), and more recently, newer derivatives have been discovered that have the 
potential as topical antiglaucoma agents, as well as antitumour, anti-obesity or anti-infective 
drugs (Supuran, 2008a,b,c). 
3. Carbonic anhydrase activators 
Carbonic anhydrase (CA, EC 4.2.1.1) inhibition with sulfonamides, discovered by Mann and 
Keilin (1940), and its activation by different classes of compounds, reported by Leiner (1940), 
although simultaneous, had completely different consequences for research of these 
enzymes and their modulators of activity. Whereas CA inhibitors (CAIs) were extensively 
studied, leading to a detailed understanding of the catalytic and inhibition mechanisms and 
also to several valuable drugs ((Supuran and Scozzafava, 2001), CA activators (CAAs) 
constituted a controversial issue immediately after they were first described (Kiese, 1941). 
Thus, activation of crude human red cell enzyme (a mixture of isozymes CA I and CA II) by 
different compounds, such as histamine, amino acids, and some purine derivatives, has 
been reported and retracted several times by the above mentioned and other authors (van 
Goor, 1948; Supuran and Scozzafava, 2000), without arriving at a clear-cut answer regarding 
the mere existence of such a class of CA activity modulators. This topic, then, received little 
attention from the scientific community for at least two reasons: (i) the statement by Clark 
and Perrin (1951) that activators of CA do not exist and (ii) the idea that the reported 
activation is not a phenomenon per se but an artifact generally due to restoration of CA 
activity possibly lost in the presence of adventitious metal ions or other impurities (or due to 
enzyme adsorption at interfaces, or even due to enzyme denaturation followed by 
renaturation in the presence of activators) (Maren, 1967) Leiner (1940), the researcher whose 
role in discovering this important class of modulators of CA activity should be completely 
revaluated, observed among others that the activation was readily detected when working 
with highly purified enzyme preparations, and this may explain the large discrepancies 
between the different early studies describing this phenomenon. Only recently Supuran’s 
group reported the X-ray crystallographic structures of adducts of the human isozyme hCA 
II with different activators, proving undoubtedly the existence of this class of modulators of 
enzyme activity as well as elucidating their mechanism of action at the molecular level 
(Maren, 1967; Briganti et al., 1997; Briganti et al., 1998; Scozzafava and Supuran, 2002). The 
very recent report (Briganti et al., 1998) that some CAAs (such as phenylalanine and 
imidazole) administered to experimental animals may produce an important 
pharmacological enhancement of synaptic efficacy, spatial learning, and memory proves 
that this class of relatively unexplored enzyme modulators may have pharmacological 
applications in conditions in which learning and memory are impaired, such as for example 
Alzheimer’s disease or aging. One must also mention that it was previously reported that 
the levels of CA are significantly diminished in the brain of patients affected by Alzheimer’s 
disease (Sun and Alkon, 2001), and these facts strongly support the involvement of different 
CA isozymes in cognitive functions (Briganti et al., 1997; Briganti et al., 1998; Sun and 
Alkon, 2001; Meier-Roge et al., 1984; Scozzafava and Supuran, 2002). 
The binding of CA activators (CAAs) to various isozymes, such as CA I, II and IV, was 
studied by kinetic and X-ray crystallographic techniques (the last techniques were applied 
only for the cytosolic isozymes I and II) (Ilies et al., 2002; Scozzafava and Supuran 2002a,b; 
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Temperini et al., 2007), which showed the activator to intervene in the rate-determining step 
of the catalytic cycle, that is, the shuttling of protons between the active site and the reaction 
medium, a process which in most CA isoforms is assisted by a histidine residue (His64, CA I 
numbering) placed in the middle of the active site cavity (Scozzafava and Supuran 2002a,b; 
Temperini et al., 2007). CAAs, there is the possibility of alternative proton transfer 
pathways, involving a protonatable moiety of the activator bound within the enzyme active 
site, which explains the enhanced overall catalytic efficiency, reflected in the augmentation 
of kcat, without any effect on KM, for all isoforms investigated up to now in detail (i.e., CA I, 
II, IV, VA, VII, XIII, and XIV) (Ilies et al., 2002; Scozzafava and Supuran 2002a,b; Temperini 
et al., 2007). X-Ray crystallography of adducts of human CA (hCA) II with histamine (19) 
(Birganti et al., 1997), L- and D-phenylalanine (20) (Temperini et al., 2005), and L- and D-
histidine (21) (Temperini et al., 2006a), as well as the adduct of hCA I with L-His (21) 
(Temperini et al., 2006b), allowed a better understanding of the CA activation phenomenon 
at the molecular level, bringing also new insights into problems of ligand recognition by an 
enzyme active site, since it has been observed that enantiomers such as L-/D-His and L-/D-
Phe bind in a very different manner to hCA II, interacting with different amino acid residues 
from the activator binding site. In addition, the interaction between the two best studied 
isozymes, that is, hCA I and II, with the same activator, L-His, was also very different, with 
the activator binding deep within the active site cavity in the case of hCA I, and toward the 
external of the cavity for hCA II. These studies are helpful for the design of better CAAs or 
for obtaining compounds with selectivity for an isozyme, and less affinity for another one 
which is not desirable to be activated (or inhibited) (Scozzafava and Supuran 2002a,b; 
Temperini et al., 2005a,b; Temperini et al., 2007). 
L-Adrenaline (22), one of the neurotransmitter catecholamines released by the sympathetic 
nervous system and adrenal medulla in response to a range of stresses in order to regulate the 
host physiological functions, is involved in regulation of blood pressure, vasoconstriction, 
cardiac stimulation, relaxation of the smooth muscles (such as the bronchial ones) as well as in 
several metabolic processes (Hoffman, and Lefkowitz, 1996). As a consequence, 4 has a variety 
of clinical uses, such as among others for relieving respiratory distress in asthma, in treating 
hypersensitivity reactions due to various allergens, cardiac arrest, or as a topical hemostatic 
agent, etc . (Hoffman, and Lefkowitz, 1996; Rawas-Qalaji, et al., 2006).  
The activating effects of adrenaline (22) on CA II (of bovine origin, bCA II) were first 
investigated by this group (Supuran and Puscas, 1994), being shown that the compound is a 
weaker CAA, as compared to histamine, aromatic/heterocyclic amino acids or other 
structurally related amines investigated in the same study. Temperini et al. (2007) decided to 
investigate in more detail its interaction with various physiologically relevant CA 
isozymes,1-5 such as CA I, II, IV, VA, VII, and XIV (all of them present among others in the 
brain).1  Temperini et al. (2007) reported kinetic investigations regarding the activation of 
the above-mentioned isoforms with L-adrenline (22), as well as an X-ray crystallographic 
study of the hCA II–4 adduct. Same study work may bring a better understanding of the CA 
activation processes, potentially useful for the design of pharmacological agents, whereas 
from the chemical point of view, it reveals a completely new interaction between the 
activator and the enzyme, which explains at the molecular level the lower efficacy of 
adrenaline as a CA II activator (Temperini et al., 2007). 
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Fig. 3. Schematic representation for the binding of L-adrenaline to the hCA II active site. The 
Zn(II) ligands, hydrogen bonds connecting the Zn(II) ion and the activator molecule with 
other amino acid residues/water molecules through a network of hydrogen bonds, 
stabilizing the enzyme-activator complex, are also evidenced (dotted lines). His64 is shown 
only in the ‘in’ conformation, the only one making a hydrogen bond with the activator 
molecule. The ‘out’ conformation of His64 does not interact with the activator. The 
methylamino group of 4 does not participate in any polar interaction, being rather close to 
the phenyl ring of Phe131 (bold line) (Temperini et al., 2007).  
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Temperini et al. (2007) studied may also shed new light in the recognition processes by 
metalloenzymes of ligands which do not directly interact with the metal ion, phenomena far 
less investigated up to now, since the majority of ligands interacting with metalloenzymes 
usually directly coordinate the metal ion(s) from the enzyme active site. 
The X-ray crystal structure of the CA II L-adrenaline adduct revealed the reason why this 
compound is a weaker activator as compared to histamine (19) and related biogenic 
amines/amino acids. Thus, in contrast to other activators investigated earlier, L-adrenaline 
(22) plugs the entrance of the active site cavity, obstructing it almost completely. In this 
conformation, it is unable to facilitate the shuttling of protons between the active site and 
the environment, also because the pKas of its protonatable moieties are in the range of 8.6–
11.34. On the contrary, histamine bound to the enzyme active site adopts a conformation 
that allows its imidazolic moiety (with a pKa around 7) to easily participate in proton 
shuttling, similarly with residue His64, the natural proton shuttle amino acid in the CA II 
active site. These findings explain thus that both the steric requirements (orientation in 
which the activator binds within the active site) and electronic factors (pKa of the proton 
shuttle moiety) are important for a compound to act as an effective CA activator, and may 
shed new light in the recognition processes by metalloenzymes of ligands which do not 
directly interact with the metal ion (Temperini et al., 2007). 
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